Meihua Medical Technologies Receivables 2021-2024 | MHUA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Meihua Medical Technologies receivables from 2021 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Meihua Medical Technologies receivables from 2021 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$227.2B
Boston Scientific (BSX)	$140.7B
Stryker (SYK)	$132.3B
EssilorLuxottica (ESLOY)	$128.4B
Medtronic (MDT)	$105.9B
Lonza Group Ag (LZAGY)	$47.4B
Haleon (HLN)	$46.2B
ResMed (RMD)	$31.3B
Agilent Technologies (A)	$29.2B
GE HealthCare Technologies (GEHC)	$28.6B
Terumo (TRUMY)	$28.2B
Koninklijke Philips (PHG)	$22.2B
Zimmer Biomet Holdings (ZBH)	$19.4B
Insulet (PODD)	$17.3B
Baxter (BAX)	$14.8B
Smith & Nephew SNATS (SNN)	$11.4B
Sunny Optical Technology (SNPTF)	$7.6B
Lantheus Holdings (LNTH)	$6.9B
Bio-Rad Laboratories (BIO)	$6.7B
Demant (WILYY)	$6.6B
Prestige Consumer Healthcare (PBH)	$4B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Perrigo (PRGO)	$3.5B
ICU Medical (ICUI)	$3.4B
Haemonetics (HAE)	$2.9B
Envista Holdings (NVST)	$2.6B
GN Store Nord (GNNDY)	$2.2B
LeMaitre Vascular (LMAT)	$1.9B
QuidelOrtho (QDEL)	$1.7B
AtriCure (ATRC)	$1.6B